Could drug holidays improve thyroid cancer treatment?

NCT ID NCT01813136

Completed Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study compares two ways of taking the drug pazopanib for people with advanced differentiated thyroid cancer that no longer responds to radioactive iodine. One group takes pazopanib continuously, while the other takes planned breaks and restarts the drug only if the cancer progresses. The goal is to see if taking breaks can reduce side effects without making the cancer worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pazopanib
What this could lead to: If successful, this could show that intermittent dosing of pazopanib is as effective as continuous treatment, potentially reducing side effects and improving quality of life for patients.
What could go wrong: This is a phase 2 trial with a moderate number of participants, so results may not confirm superiority or non-inferiority. The intermittent schedule might lead to faster disease progression in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CARCINOMA

Contacts and locations

Locations

CHRU Lille Hôpital Claude Huriez

Lille, 59037, France
CHU Angers

Angers, 49933, France
CHU Bordeaux

Bordeaux, 33075, France
Centre Antoine Lacassagne

Nice, 06189, France
Centre François Baclesse

Caen, 14076, France
Centre Leon Berard

Lyon, 69373, France
Hôpital Saint-Louis APHP

Paris, 75010, France
Hôpital de la Pitié Salpêtrière APHP

Paris, 75651, France
Hôpital de la Timone APHM

Marseille, 13385, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Régaud

Toulouse, 31052, France
Institut Gustave Roussy

Villejuif, 94805, France
Institut Jean Godinot

Reims, 51726, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.